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Abstract: Bone pathology is frequent in stressed individuals. A comprehensive examination
of mechanisms linking life stress, depression and disturbed bone homeostasis is missing. In this
translational study, mice exposed to early life stress (MSUS) were examined for bone microarchitecture
(µCT), metabolism (qPCR/ELISA), and neuronal stress mediator expression (qPCR) and compared
with a sample of depressive patients with or without early life stress by analyzing bone mineral
density (BMD) (DXA) and metabolic changes in serum (osteocalcin, PINP, CTX-I). MSUS mice showed
a significant decrease in NGF, NPYR1, VIPR1 and TACR1 expression, higher innervation density in
bone, and increased serum levels of CTX-I, suggesting a milieu in favor of catabolic bone turnover.
MSUS mice had a significantly lower body weight compared to control mice, and this caused minor
effects on bone microarchitecture. Depressive patients with experiences of childhood neglect also
showed a catabolic pattern. A significant reduction in BMD was observed in depressive patients with
childhood abuse and stressful life events during childhood. Therefore, future studies on prevention
Int. J. Mol. Sci. 2020, 21, 6634; doi:10.3390/ijms21186634 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2020, 21, 6634 2 of 24
and treatment strategies for both mental and bone disease should consider early life stress as a risk
factor for bone pathologies.
Keywords: psychosocial stress; bone pathologies; osteoporosis; bone mineral density;
childhood; neuroendocrine
1. Introduction
Bones are essential components of the musculoskeletal system and subjected to continuous
remodeling as an adaptation mechanism to environmental changes. Disturbances in bone development
and remodeling by formation/resorption of the extracellular matrix (ECM) or differentiation of
osteoblasts into osteocytes and apoptosis of osteocytes could result in reduced bone mass and increased
fracture risk.
Beside well-documented mechanisms like menopause-associated hormonal changes, aging-related
factors, changes in physical activity, as well as drugs and diseases, recent research suggested that
psychosocial stress and stress-linked neuronal processes are associated with an increased risk for bone
pathologies [1–5]. Autonomic and sensory nerve fibers densely innervate bone, predominantly in the
periosteum and in areas with high metabolic activity and bone turnover. Neuronal structures can
make direct contact with osteoblasts and osteoclasts, which in turn express receptors for neuronal
markers on their surface, and can produce neuronal mediators in an auto- and paracrine fashion [6–10].
Importantly, sympathetic and peptidergic neuronal factors can act as stress mediators and appear
to play a key role in bone turnover [11–13]. Of specific relevance are tyrosine hydroxylase (TH),
a rate-limiting enzyme for noradrenaline synthesis, neuropeptide Y (NPY), often co-expressed with
noradrenaline, vasoactive intestinal peptide (VIP), often co-expressed with acetylcholine, and the
neuropeptides calcitonin gene related peptide (CGRP) and substance P (SP) that are expressed in
sensory nerve fibers. In addition, neurotrophic growth factors such as nerve growth factor (NGF) and
brain derived neurotrophic factor (BDNF) that guide outgrowing nerve fibers to bony areas requiring
innervation are of interest. Stress alters their expression, and they can also act as direct and indirect
growth factors for osteoblasts [14–26]. Latest studies indicate that psychosocial stress can lead to
structural and functional changes in neuronal plasticity, neuronal marker expression, mitochondria
and inflammation [4,27,28], possibly resulting in downstream alterations of bone homeostasis [29–33].
In humans, major early life stress like childhood maltreatment strongly affects the stress response,
as well as behavioral and cognitive functions throughout life [34,35]. Strong associations were shown
between childhood maltreatment and higher risk for psychological and physiological disorders
including depression, hypersensitivity of the neuroendocrine, autonomic and peptidergic stress
response leading to altered dynamics of the hypothalamic pituitary adrenal (HPA) axis, and changes
in the neuronal mediators that can influence bone health [36]. Childhood maltreatment is one of the
best-documented risk factors for depression [37–40] and depression, in turn, has been associated with
a higher risk for reduced bone mineral density (BMD), osteoporosis and bone fractures [41–45].
However, existing knowledge about the underlying mechanisms between early life stress,
neurogenic stress response elements, and detrimental changes in bone metabolism and
microstructure/BMD has been limited by several reasons. First, although early life stress like childhood
maltreatment is a frequent phenomenon, it is hardly accessible to retrospective and longitudinal
studies due to its rare diagnosis and ethical requirements for case-control studies. Second, access to
biological material and strict control of confounding factors, such as physical activity and eating habits,
are challenging in human studies [46,47]. Animal models offer an obvious way to investigate major
stress experiences early in life despite these obstacles. Animal models are helpful counterparts of
human studies to investigate underlying mechanisms in a highly controlled environment that allows
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extensive tissue sampling, strict definition of adverse events and confounding factors, and lower
subject variability.
Unpredictable maternal separation and maternal stress during early life (mice exposed to early
life stress (MSUS) paradigm [48]) is an experimental stress paradigm in rodents that can mimic aspects
of childhood maltreatment and induce long-lasting health effects, such as increased depression-like
behavior (anhedonia) and altered brain activity in adulthood [49]. The MSUS paradigm severely
impacts physiology and behavior in the exposed animals, but also in their descendants across several
generations via mechanisms involving epigenetic factors in the germline [48,50–52].
To address the knowledge gap between early life stress, stress-dependent neurogenic markers that
mark neuronal plasticity and detrimental changes in bone metabolism and bone microstructure/BMD,
we first examined the impact of early life stress on neuronal mediator expression (qPCR) and bone
microarchitecture (µCT), metabolism (qPCR on bone, ELISA on serum for osteocalcin OC, PINP,
CTX-I), and in mice using the MSUS paradigm (Aim 1). Then, we translated the findings to humans
by analyzing metabolic changes in serum (OC, PINP, CTX-I) and microarchitecture (DXA) in a
sample of depressive patients, with or without retrospectively reported experiences of early life stress,
like childhood maltreatment and stressful life events during childhood (Aim 2).
2. Results
2.1. Mouse Study
2.1.1. Bone innervation and Neuronal Mediators
We first assessed the effects of early life stress on neuronal signaling and neurogenic factors in
bone metabolism by measuring neuronal density and expression patterns of neurogenic markers in the
bone of MSUS and control mice (n = 6–8 each).
To study changes in neuronal marker gene expression, qPCR was performed. Gene expression
analysis revealed that key receptors for nerve growth factors, neurotransmitters and neuropeptides
(Figure 1) and selected receptors’ ligands (Figure 2) were changed in MSUS mice in a pattern
that may promote higher bone turnover and lower bone density. In detail, mRNA expression of
the receptors NPYR1 (p < 0.05, Figure 1B), VIPR1 (p < 0.001, Figure 1C) and TACR1 (p < 0.01,
Figure 1D) were significantly reduced in MSUS mice whole bone homogenates (after the removal
of bone marrow), suggesting their presence on osteocytes. These three receptors are involved in
the regulation of proliferation and differentiation in bone, and their concomitant downregulation
may lead to higher remodeling activity with less proliferation and more differentiation of bone cells.
Furthermore, a significant reduction of the neurotrophin NGF (p < 0.001, Figure 2A) was revealed,
while NPY showed a downtrend in MSUS (p = 0.068, Figure 2B). This would hamper both neuronal
plasticity and bone remodeling when facing challenge such as a wound or aging leading to osteoporosis.
Other markers of bone innervation and metabolism such as NGFR, ADRB2, CHRNA7, RAMP1,
and TAC1 were similar in control and MSUS mice, whereas TRKA, TRKB, TH, ChAT and VIP were
below the detection limit.
We subsequently investigated bone innervation by immunohistomorphometry. The density of
nerve fibers labeled with the pan-neuronal marker protein gene product 9.5 (PGP 9.5) was significantly
increased in the bone of MSUS mice (Figure 3), whereas nerve fibers labeled with the neuronal
plasticity marker GAP 43 were unaffected (not shown), indicating that higher innervation was not
due to increased neuronal plasticity, but was likely a stable feature. Higher innervation density
potentially leads to higher sensitivity of bone neurons to stimuli like injury. Notably, the neuropeptides
NPY, VIP and SP were undetectable by immunohistochemistry, most likely due to insufficient bone
preservation. This likely results from the post-mortem fixation method used for ethical requirements,
which does not preserve small peptides (the eleven amino-acid sequences of SP, for example, are rapidly
digested by endogenous enzymes after termination of circulation) [53–55].
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Figure 1. : Differential gene expression of neuronal receptors in bone between control and mice
exposed to early life stress (MSUS) mice. Shown are the gene expression of neurotrophin receptors (A),
noradrenergic receptors (B), cholinergic receptors (C) and receptors involved in sensory innervation
(D). Data (n = 8 per group) are expressed as Min to Max of 2−dCt. Significance level: *** p < 0.001,
** p < 0.01 and * p < 0.05 between indicated groups.
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Figure 2. Differential gene expression of neuronal ligands in bone between control and MSUS mice.
Shown are the gene expression of neurotrophins (A), noradrenergic ligands (B), cholinergic ligands (C)
and ligands involved in sensory innervation (D). Data (n = 8 per group) are expressed as Min to Max of
2−dCt. Significance level: *** p < 0.001 between indicated groups.
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Figure 3. Increased bone innervation in MSUS mice. Representative images of the third tail
bone from control and MSUS mice labeled with protein gene product 9.5 (PGP 9.5) pan-neuronal
marker for immunofluorescence histomorphometry of nerve fibers (nerve fibers (NF)-red) in bone.
Nuclei are counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (blue), mast cells with fluorescein
isothiocyanate (FITC)-avidin (green) (A). Shown are the increased mean numbers of immune-positive
profiles per compartment unit of single NF in bone (B), NF bundles at entry to bone (C) and single NF in
bone marrow (D). Data (n = 8 Control, n = 6–7 MSUS) are expressed as Min to Max of number of positive
profiles per compartment unit. Significance level: ** p < 0.01 and * p < 0.05 between indicated groups.
2.1.2. Bone Metabolic Parameters
We then examined if changes in neuronal markers were associated with bone metabolic changes by
measuring markers in serum and bone. Serum levels of osteocalcin and PINP, two markers associated
with bone formation, did not change after MSUS (Figure 4A,B). In contrast, the level of CTX-I, which is
associated with bone resorption, was significantly increased in MSUS mice compared to control mice
(p < 0.01, n = 14 each; Figure 4C).
Figure 4. Bone formation and resorption markers in serum of mice. Shown are serum concentration
measurements of osteocalcin (A), procollagen type 1 N-terminal propeptide (PINP) (B) and c-terminal
telopeptide of type I collagen (CTX-I) (C) in mice. Data (n = 14 per group) are expressed as Min to Max
of concentration in serum [ng/mL]. Significance level: ** p < 0.01 between indicated groups.
However, this catabolic shift was not reflected by altered gene expression of tissue-specific
extracellular matrix markers (osteocalcin, osteoprotegerin, osteopontin, sclerostin) in bone samples of
MSUS (Figure 5A–D) (n = 8 each).
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Figure 5. Gene expression of extracellular matrix in bone of mice. Shown are the gene expressions of
tissue-specific extracellular matrix markers in bone of controls and MSUS. Genes include osteocalcin (A),
osteoprotegerin (B), osteopontin (C) and sclerostin (D). Data (n = 8 per group) are expressed as Min to
Max of 2−dCt. Significance level: all p > 0.05.
2.1.3. Bone Microarchitecture
Next, it was examined if MSUS affects bone microarchitecture in mice using µCT (n = 14 MSUS,
n = 13 Control). As bone microarchitecture is sensitive to mechanical loading, we also measured
the body weight of experimental animals over time. Body weight was significantly lower in MSUS
mice compared to control mice starting at postnatal day 7 (PND7), and remained lower in adulthood
(p < 0.001 for PND 7–28 and p < 0.05 for 10 months, Supplementary Figure S1), and this caused minor
effects on bone microarchitecture.
After adjusting µCT data for body weight, a comparison of means between control and MSUS
mice did not reveal any difference in full, cortical or trabecular microarchitecture (all values p > 0.05)
(Supplementary Table S1). We also used blocking in tertiles for body weight and conducted a
two-factorial multivariate analysis of variance, which revealed that, indeed, the effects of MSUS versus
controls were driven by body weight. To specify this effect, we conducted sets of linear regression
analyses to test for simple mediation effects and found that body weight mediated the effect of MSUS
on full length, TV, BV, MV and BS (all p’s for direct effects > 0.05).
2.2. Human Study
2.2.1. Descriptive Results
N = 193 out of n = 208 patients under study suffered from depression with minimal (35%) up to
moderate/severe (65%) severity (BDI-II: M = 23.8, SD = 10.7) and were included in further analysis.
For the analysis of bone metabolic parameters, blood samples from n = 145 patients were available,
of whom n = 145 filled in the Inventory of Stressful Life Events (ILE) and n = 54 the Childhood
Trauma Screener (CTS). For the BMD analysis, n = 17 patients took part in DXA bone densitometry
measurements. Out of these participants, n = 15 patients filled in the Inventory of Stressful Life
Events (ILE) and n = 17 the Childhood Trauma Screener (CTS). Missing data are due to incomplete
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questionnaires or drop out. Table 1 provides descriptive data on age, gender, antidepressant use,
weight and early life stress for the subsamples. Average bone mineral density (BMD) in the sample
was M = 0.942 g/cm2 (SD = 0.186 g/cm2) in the trochanter region of the proximal femur.
2.2.2. Bone Metabolic Parameters
Regarding changes in human bone metabolism following early life stress, bone serum markers
OC, PINP, CTX-I were analyzed. It was shown that depressed patients with childhood trauma
(CTS, CTS abuse) had an increased anabolic bone metabolism in comparison to depressed patients
without early life stress (CTS: p = 0.05* for CTX; CTS abuse: p = 0.03* for P1PN, Table 2). This anabolic
bone metabolism was likewise found for depressed patients with stressful life events during childhood
(ILE child) in comparison to depressed patients without early life stress (p = 0.04* for P1PN, Table 2).
Depressed patients with experiences of childhood neglect (CTS neglect) lacked such an anabolic
reaction (Table 2).
2.2.3. Bone Mineral Density
An explorative analysis on bone mineral density in a subsample of DXA measurements suggests
that depressive patients with stressful life events during childhood (ILE child) had reduced BMD in
the trochanter major (p = 0.03* for BMD_T) and as a tendency a reduction in general BMD (p = 0.08#
for BMD_G, Table 2). There are indications that depressed patients with a history of childhood abuse
showed specifically a BMD reduction in the trochanter major (p = 0.05* for BMD_T), and a tendency in
reduced BMD in general (p = 0.07# for BMD_G). This gives notice of long-term health consequences of
people with maltreatment and stressful life events during childhood in comparison to people with
depression lacking experiences of early life stress (Table 2, Figure 6).
Figure 6. Bone mineral density measurements in human patients. Shown is the bone mineral density
(BMD) in G (total), H (collum femoris), S (corpus femoris), and T (trochanter major) as mean of the right
and left site and L1-L4 (lumbar vertebralis bodies) stratified for at risk and not at risk for childhood
maltreatment (not controlled for gender, age, body weight). Data (n = 18) are expressed as mean
and standard deviation of BMD, stratified for Childhood Trauma Screener (CTS) (at risk for abuse or
neglect). Significance level: * p < 0.05, and # p < 0.1 between indicated groups.
Int. J. Mol. Sci. 2020, 21, 6634 9 of 24




















Sample of bone metabolic
parameters a
145 47.9 (10.1) 24.0 (10.1) 78.1 (17.4) 118 (81.4) 100 (69.0) 128 (88.3) 47 (32.4)
➥ life events during
childhood (ILE child)
128 48.1 (10.1) 24.0 (10.0) 78.2 (17.3) 104 (81.3) 86 (67.2)
➥ childhood maltreatment
(CTS)
47 47.9 (10.4) 24.6 (10.7) 75.8 (17.3) 35 (74.5) 32 (68.1)
DXA sample b 17 51.9 (6.6) 23.7 (11.7) 74.3 (17.5) 12 (70.6) 13 (76.5) 15 (88.2) 17 (100.0)
➥ life events during
childhood (ILE child)
15 52.2 (7.0) 24.9 (12.2) 71.2 (16.3) 11 (73.3) 11 (73.3)
➥ childhood maltreatment
(CTS)
17 51.9 (6.6) 23.7 (11.7) 74.3 (17.5) 12 (70.6) 13 (76.5)
a Bone serum markers OC, PINP, CTX-I; b bone mineral density (BMD) measured by Dual Energy X-ray Absorptiometry (DXA); c Inventory of Stressful Life Events; stressful life events
during childhood (≤12 years); d Childhood Trauma Screener (CTS) at least at risk for one type of neglect or abuse (sexual, physical, emotional abuse, physical, emotional neglect).
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Table 2. Main Effects (Regression Coefficient b) of Childhood Maltreatment (Abuse or Neglect) and Stressful Life Events During Childhood (≤12 years; ILE child) on
Bone Serum Marker (Osteocalcin (OC), Procollagen type 1 N-terminal propeptide (PINP), and C-terminal telopeptide of Type I Collagen (CTX-I)) and Bone Mineral
Density (BMD).
P1NP OC CTX-I
b 95%CI p b 95%CI p b 95%CI p
CTSa 9.27 −1.43; 19.97 0.10 # 2.87 −0.56; 6.30 0.11 0.10 0.01; 0.18 0.05 *
CTS abuse 11.42 1.86; 20.99 0.03 * 2.51 −0.65; 5.67 0.13 0.06 0.02; 0.14 0.16
CTS neglect −6.26 −16.45; 3.93 0.24 0.32 −3.63; 2.98 0.85 0.03 −0.06; 0.12 0.50
ILE child
b 8.37 0.71; 16.03 0.04 * 2.28 −0.10; 4.65 0.06 # 0.06 −0.01; 0.11 0.06 #
BMD_ L1L4 c BMD_T BMD_S BMD_G BMD_H
b 95%CI p b 95%CI p b 95%CI p b 95%CI p b 95%CI p
CTS −0.07 −0.23; 0.08 0.40 −0.09 −0.22; 0.04 0.20 −0.09 −0.25; 0.08 0.33 −0.10 −0.23; 0.03 0.17 −0.10 −0.22; 0.02 0.12
CTS abuse −0.07 −0.26, 0.12 0.48 −0.15 −0.28; −0.02 0.05 * −0.13 −0.32, 0.06 0.22 −0.15 −0.29, −0.01 0.07 # −0.12 −0.26, 0.01 0.10
CTS neglect −0.06 −0.21, 0.10 0.51 −0.06 −0.20, 0.07 0.39 −0.07 −0.24, 0.10 0.45 −0.07 −0.21, 0.07 0.38 −0.03 −0.16, 0.10 0.68
ILE child −0.18 −0.46, 0.10 0.25 −0.26 −0.44, −0.07 0.03 * −0.18 −0.48, 0.11 0.26 −0.22 −0.43, −0.01 0.08
# −0.17 −0.36, 0.03 0.14
Multiple regression models, adjusted for age, gender, and study sides. Significant Regression coefficients b are bold. Significance level: * p < 0.05, and # p < 0.1. a Childhood Trauma
Screener (CTS) at least at risk for one type of neglect or abuse (sexual, physical, emotional abuse, physical, emotional neglect); b Inventory of Stressful Life Events; stressful life events
during childhood (≤12 years); c Bone mineral density (BMD) was measured as mean value (M) in the lumbar spine L1-L4 (lumbar vertebralis bodies), T (trochanter major), S (corpus
femoris), G (total), and H (collum femoris).
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3. Discussion
The first aim of this study was to investigate the effects of early life stress on bone health and
associated biological factors in a mouse model of early life stress (MSUS). The second study aim was
the translation of the gained knowledge in a human model using a sample of depressive patients with
and without early life stress.
Aim 1: In summary, we found that early life stress in the MSUS model altered bone innervation
and neuronal mediator expression as well as bone metabolism, as evidenced by increased CTX-I
serum concentrations, but did not affect the expression of bone markers within the bone or bone
microarchitecture. In detail, we found significantly decreased expression of NGF, NPYR1, VIPR1
and TACR1 in MSUS bones. This response pattern is suggestive for a higher rate of bone turnover
and lower bone healing capacities as a consequence of early life stress, suggesting a concurrent joint
downregulation, reduced bone remodeling and long-term destabilization. The neurotrophin NGF is
important for the expression of cholinergic and sensory neuronal factors, and hence for the development
and the repair of bone, as demonstrated by reduced bone length when absent [14–26]. The neuropeptide
NPY promotes osteoblast differentiation and balances the effects of stress-induced bone loss through
beta-adrenergic stimulation, both with consequences for bone remodeling during healing [10,53,56–63].
The neuropeptide VIPR1, finally, promotes bone mineralization [64–68], while TACR1 regulates the
osteoblasts, osteoclasts and mesenchymal stem cell functionality associated with protection from
osteoporosis [2,62,69–85].
While MSUS mice showed a clear neuroendocrine response pattern, the gene expression of typical
bone markers (in bone) was unaffected. Similarly, we did not observe increased osteocalcin in the serum
of MSUS mice. However, CTX-I serum levels were significantly increased in MSUS mice. CTX-I is an
increasingly promoted and robust biochemical factor for bone resorption in clinical settings [86–89].
Additional analyses, such as bone histomorphometry to determine whether MSUS leads to alterations
in the numbers of osteoblasts (type 1 procollagen staining) and/or osteoclasts (TRAP staining) [90]
could provide useful insights into bone adaptation processes.
Regarding bone microarchitecture, no significant changes were observed after normalization to
body weight. Body weight itself, which was affected by MSUS, did cause minor changes in bone
microarchitecture, likely due to differences in mechanical loading of the skeleton. It is unclear if altered
body weight might be a post stress consequence for MSUS or an incidental finding. This should be
considered in future studies, as it can be a confounding factor in µCT analyses. We considered whether
the observed lack of differences in bone microarchitecture (despite an increase in serum CTX-I) might
be due to divergent timelines of these events [91] or might be sex-dependent (different susceptibility
to bone alterations and/or sensitivity to stress) [92,93]. Therefore, we additionally conducted µCT
scans of the femurs of female mice over a more extended time range (up to 16 months). We did
not find any differences in bone microarchitecture in the female mice, even not at later time points
(data not shown). It is important to keep in mind that changes in bone microarchitecture may be
site-specific, and may hence have been overlooked by restricting the µCT analysis to the femur only.
Perhaps, the use of models of aging (e.g., the senescence-accelerated mouse = SAM) [94], models that
include bone injury requiring repair (such as osteotomy) [95], or a comparison of stress-resilient and
stress-prone subpopulations [96] might potentially have led to observable changes in bone structure
within a reasonable time frame [13], but further investigations will be needed to allow for more
definite statements.
Aim 2: In summary, we found that people who experienced childhood maltreatment or stressful
life events during childhood showed an overshooting anabolic bone metabolism during a depressive
episode, rather than the expected minor, short-term metabolic adaptation. For example, people
in our study showed a threefold higher metabolic reaction in PINP during the depressive episode,
in comparison to depressed adults without childhood maltreatment [5]. This was evidenced by
increased serum levels in bone metabolism markers (distinctly in PINP and CTX-I, less in OC).
Furthermore, our data suggest that depressive adults with experiences of childhood maltreatment
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(childhood abuse) and stressful life events during childhood showed a significantly decreased BMD
in the long term. In contrast, for depressive adults with no experiences of childhood neglect, these
patterns were not observed. In other words, and regarding latest studies, an overshooting or lacking
metabolic adaptation during a depressive episode may serve as a link for the often-observed reduction
of BMD in depressed patients in the long term [5]. These mechanisms fit the hypotheses of the
destructive effects of a hypersensitive central stress response (overshooting) or a blunted response
(lacking adaptation) on organs and bodily tissues.
Other human studies have linked childhood maltreatment to neuroendocrinological and
neuroanatomic alterations that overlap with depressive symptoms and result in a vulnerable phenotype
that is affected by a hypersensitive central stress response, blunted stress reactivity and lower stress
resilience [97–99]. It was suggested that further severe distress, such as additional traumatization,
or the development of depression, may promote an over-adaptive reaction. The response pattern in
our data seems to confirm this assumption, which can result from various aspects, such as an altered
mitochondrial function, gene dysregulation, the accumulation of oxidative stress, inflammation and
senescence or changes in neuronal plasticity [27,28]. The associations between stressful events early in
life and an early decrease of noradrenergic, cholinergic and sensory neuronal factors were also observed
in our animal model. It is also comprehensible that no such pattern could be found for childhood
neglect, as it represents acts of omissions that are typically temporary, such as lack of nutrition, medical
or emotional care. Hence, this might have a lower impact on a person’s psychological integrity, identity
and health than childhood abuse. Furthermore, the data match well with further results within this
study sample: patients that suffer from chronic stress (measured by the allostatic load index) showed
a catabolic shift in bone metabolism during a depression episode [5]. This can be explained by the
fact that other mechanisms are expected for allostatic load as an accumulating damage over time with
the consequence of neuroendocrinological and neuroanatomic alterations [36,98,100]. The observed
reduced BMD can be expected in both response patterns: within a hypersensitive stress response and
within an increased allostatic load. Both mechanisms were demonstrated in data of people of the
presented DEPREHA-study.
In summary, we found that early life stress affects bone metabolism in mice and humans. In MSUS
mice, this was evidenced by a significant shift towards a neurogenic and osteogenic catabolic milieu
(decreased NGF, NPYR1, VIPR1, TACR1; higher innervation density in bone; increased serum CTX-I),
but no alterations in bone microarchitecture in relatively young mice not exposed to additional life
stresses. In humans however, for those who suffered both from early life stress and depression,
a significant reduction in BMD was observed. Taking the age range and morbidity (depression) of the
human sample under consideration, the differences between mice and human could be interpreted as
patterns of vulnerability and acute consequences (mouse model) compared to long-term burden of
early life stress (human). Otherwise, species-related differences in bone metabolism between mice
and humans have been described [101]. Our data support the notion that the mechanisms of bone
loss seem different between mice and humans, as mice did not show any decrease in trabecular
thickness, which is considered as typical for ageing humans [102]. However, this contrasts with
Halloran et al. [102], who showed that cancellous bone volume fraction is reduced in 24 months old
male C57BL/6J mice and is hence comparable to humans. Furthermore, the observed differences
in the response of mice and humans are likely caused by differences in types of stress early in life.
In fact, we were able to demonstrate clear differences between different types of early life stress in
the human sample, further supporting this theory. Although the results obtained in the mouse study
do not overlap entirely with the human results, they provide relevant and promising potential for
translation. Furthermore, the animal model can be used to identify probable mechanisms underlying
osteoporosis development, following early life stress (i.e., related to innervation patterns) that could
not be investigated easily in humans, thereby allowing one to develop ideas for future studies or even
intervention and prevention strategies.
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In conclusion, this study demonstrates that stressful life events early in life lead to (mal-) adaptive
responses in bone metabolism in both mice and humans. However, the major conclusion to be
drawn from the presented data is that different types of early life stress lead to different response
patterns concerning bone health. Thus, they have to be consider separately and possibly consecutively:
MSUS mice responded with enhanced bone resorption, which however did not cause changes in bone
microarchitecture 8–10 months after the stress exposure when later kept under stress-free conditions.
In humans, a reduction in BMD was evident only in depressive patients with severe stress exposure in
early life like childhood abuse and stressful life events during childhood. Similarly, the changes in
bone serum markers were also dependent on the severity of stress experiences early in life. People with
childhood abuse and stressful life events during childhood showed an increased bone metabolism,
while people with childhood neglect showed a counter regulated reaction. Hence, the consequences
of the observed changes in the context of challenges to bone health (fractures, aging etc.) should be
studied in a more personalized manner. Future prevention strategies should respect the severity of
the stress exposure to be treated (e.g., specific types of stress experiences during childhood, double
hit paradigms), to achieve the optimal benefit for patients with increased risk for bone pathologies
(such as people with depressive disorders).
4. Materials and Methods
4.1. Mouse Study
4.1.1. Animal Model
Animal experiments were conducted in strict adherence to the Swiss Law for Animal Protection
and were approved by the local authority (Veterinäramt des Kantons Zürich, Zürich, Switzerland)
under license number 57/2015. C57Bl/6J mice were obtained from Janvier Labs (Le Genest-Saint-Isle,
France) and bred in-house to generate the male mice (n= 47 MSUS, n= 46 Control) used for experiments.
The MSUS paradigm was conducted as previously described [48]. As shown in Figure 7, 2–3 months
old C57Bl/6J naïve females were mated with naïve males for 1 week. Mothers were assigned to control
or MSUS group based on the number of male pups born on that day to balance the groups. The MSUS
paradigm started on postnatal day 1 (PND1): Pups were separated unpredictably from their mother for
3 h per day from PND1 until PND14. Separation occurred at any time during the dark cycle. In addition,
mothers were subjected to forced swim in cold water (18 ◦C for 5 min) or restraint in a plastic tube
(20 min) at unpredictable times during the 3 h of separation. Control mice were left undisturbed
except for weekly cage changes and weight measurements. Pups were weaned at PND21 and assigned
to sex and treatment matched cages (4 to 5 mice) between PND22 and PND28. The co-assignment
of siblings was avoided to exclude litter effects. At the age of 8–10 months, control (n = 24) and
MSUS (n = 24) males were deeply anesthetized by Isoflurane (Attane, Piramal Enterprises Limited),
followed by decapitation. Males were single-housed the day before sacrifice to reduce potential acute
stress effects [103]. Body weight was monitored throughout the experiment and on the day of single
housing. Adult mice were housed in groups of 3 to 5 animals in individually ventilated cages (SealSafe
PLUS, Tecniplast). Animals were kept in a temperature- and humidity-controlled facility on a 12 h
reversed light/dark cycle (light on at 20:00), with food (M/R Haltung Extrudat, Provimi Kliba SA) and
water ad libitum. Cages were changed weekly.
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Figure 7. MSUS (unpredictable maternal separation and unpredictable maternal stress) is a mouse
model of early life stress. Naïve males are mated with naïve females for 1–7 days, then males are
removed. Dams gestate for about 21 days in normal conditions until delivery. The MSUS paradigm
(red bar in the timeline) starts at postnatal day 1 (PND1) and lasts until PND14. During MSUS, pups are
unpredictably separated from their mothers for 3 h each day at different times of the dark cycle (lights
off from 8 a.m. to 8 p.m.). During separation, the mother is stressed unpredictably by forced swim or
restraint as shown in the timeline at the bottom. Pups and dam are left undisturbed from PND15 until
weaning at PND21. Gray mice are naïve without any previous stress exposure. Blue pups are controls
without any stress exposure. Red pups are exposed to MSUS.
4.1.2. Collection of Serum Samples
Trunk blood was collected in 2 mL tubes immediately after decapitation and incubated at 4 ◦C.
Clotted blood was centrifuged at 2000 rcf at 4 ◦C for 10 min. The collected serum was stored at −80 ◦C.
4.1.3. Collection of Bone Samples
After euthanasia and blood collection, the left femur was dissected on ice under aseptic conditions
and cleaned from muscle tissue. The ends were cut off to allow for removal of bone marrow (flushed
out with sterile phosphate buffered saline, PBS), and the entire flushed femur (including the ends) was
subsequently shock-frozen in liquid nitrogen and stored at −80 ◦C until further processing for qPCR.
Right femurs were dissected, cleaned and stored in 70% ethanol at 4 ◦C until µCT analysis. The third tail
bone was dissected and immersed in a mixture of 4% paraformaldehyde and 14% saturated picric acid
overnight at 4 ◦C, cryoembedded and stored at −80 ◦C until further processing for histomorphometry
was done.
4.1.4. Histomorphometry of Neuronal Markers
For bone innervation morphometry, the immunohistochemistry of pan-neuronal marker and
exemplary markers for adrenergic, cholinergic and peptidergic nerve fiber subsets were performed with
decalcified 14 µm thick transverse mouse tail cryostat sections, analog to previous descriptions [55].
The sections were done through the center of the third tail bone and contained the bone with the
adherent muscle, tendons and skin for internal positive control. The primary antibodies used in
this study were: anti-PGP 9.5 (Biotrend, Cologne, Germany), anti-GAP 43 (Millipore, Darmstadt,
Germany), anti-ChAT (Serotec, Kidlington, UK), anti-TH (Abcam, Cambridge, MA, USA) and anti-SP
(BMA Biomedicals, Augst, Switzerland). Only PGP 9.5 and GAP 43 gave satisfactory staining
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results, most likely due to insufficient fixation of more digestion prone markers in bone compared
to the skin (positive controls were all positive), which commonly require transcardial fixation [104].
Standard controls were performed by omission of the primary antibodies and by incubation with
mouse IgG1 instead of primary antibodies. No labeling was observed in negative controls. Nerve fiber
profiles were counted per area with the help of a grid equipped ocular at x200 magnification using
a Leica inverted automated fluorescence-microscope (Leica, Wetzlar, Germany). Briefly, numbers of
positively stained fibers were counted per grid field in at least 30 consecutive fields per experimental
mouse and in at least n = 8 mice per experimental group by two blinded independent researchers.
The data were then pooled and expressed as means per group ± standard error of the mean.
4.1.5. qPCR for Gene Expression in Bone Samples
Mouse femurs were pulverized using a metal ball mill (Retsch, Haan, Germany), and total RNA
was isolated with Trizol/chloroform extraction, followed by column-based purification using RNeasy
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol, but including proteinase
K incubation (55 ◦C, 15 min). Contaminating DNA was removed by using the RNAse-free DNAse
kit (Qiagen, Hilden, Germany), and 32 µL of RNA with an average yield of 48 ng/µL were reverse
transcribed with Superscript II reverse transcriptase (Thermo Fisher Scientific, Dreieich, Germany) to
obtain 80 µL of cDNA. qPCR analysis was performed in duplicate, using the TaqMan Fast PCR Master
Mix with Taqman assays for bone markers (Life Technologies, Germany) (Supplementary Table S2) or
the QuantiTect PCR Kit with self-designed primers for neuronal factors (Qiagen, Hilden, Germany)
(Supplementary Table S3). The amount of cDNA per reaction depended on the respective target gene
and its expression level and was 1–18 ng. Gene expression was normalized to the housekeeping gene
(dCt) and 2−dCt were computed.
4.1.6. ELISA of Serum Samples
Commercially available ELISA kits were used to determine the serum levels of OC (60-1305,
Immunotopics/Teca, Switzerland), PINP (AC-33F1, Immunodiagnosticsystem, Frankfurt, Germany)
and CTX-I (AC-06F1, Immunodiagnosticsystem, Frankfurt, Germany), according to the manufacturers’
instructions. Serum was used either undiluted (CTX-I) or at a 1/11 (osteocalcin) or 1/10 (PINP) dilution.
4.1.7. µCT of Bone Samples
Analysis of bone microarchitecture by µCT was conducted as previously described [105]. Briefly,
bones were measured on a µCT40 (Scanco Medical AG, Brüttisellen, Switzerland), operated at 55 kVp
and 145 µA with an integration time of 200 ms and 2-fold frame averaging. Images were reconstructed
at an isotropic nominal resolution of 10 µM and filtered using a constrained 3D Gaussian filter (sigma
0.8, support 1) to suppress noise. Masks of the full bone, cortical (shaft at 56% bone length, 1 mm
long) and trabecular region of interest (from 66% to 88% of bone length) were created automatically.
Morphometric parameters were calculated according to standard guidelines such as total volume (TV),
bone volume (BV), marrow volume (MV), apparent volume density (AVD), femur length, cortical area
fraction (Ct.Ar/Tt.Ar), cortical thickness (Ct.Th), trabecular bone volume fraction (BV/TV), specific bone
surface (BS/BV), trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp) and trabecular number
(Tb.N) [106]. Due to differences in body weight between the control mice and the MSUS mice, data was
normalized for body weight, and body weight adjusted means were compared.
4.2. Human Study
4.2.1. Participants
n = 240 patients with depressive disorder (ICD-10 F32.x, F33.x, F34.1, F43.21) were recruited,
of which n = 208 completed the initial examination (baseline (t0)), for more details see [5]. A subsample
of n = 54 patients took part at the fourth follow up measurement (t4) including DXA imaging.
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Patients who fulfilled the following criteria were included: 18 to 65 years of age, depressive episode
(ICD-10 F32.x or F33.x), dysthymia (F34.1), or an adjustment disorder with prolonged depressive
reaction (F43.21), ≥21 days absenteeism within the last year. Exclusion criteria were: pregnancy,
hormonotherapy (expect contraceptive and thyroid hormone therapy), inability to fill in a questionnaire,
intellectual disabilities (ICD-10 F70-79), or one of the following diseases: acute infection, endocrine and
metabolic disorders, neurological diseases, dementia (ICD-10 F00-F03), schizophrenia (ICD-10 F20),
emotional-unstable personality disorders (ICD-10 F60.3x), disease of the immune system, substance
abuse and dependency (except nicotine).
All participants were fully informed in verbal and written form about the intent and content of the
study, and gave their written informed consent. The clinical investigations were conducted according
to the principles of the Declaration of Helsinki. Final ethical approval was provided on 11/12/2017
from the Ethics Review Board of the University of Potsdam, Germany (number 15/2017).
4.2.2. Study Procedure
Study objectives were investigated at two assessments (t0 and t4) of an 8-month observational
multicenter study with four measurement points: baseline (t0), after 5 weeks (t1), 5 months (t2),
8 months (t3) and an additional follow-up measurement (t4: M = 15.4 month, SD = 4.5 month after
baseline). At each measurement point, study participants answered a comprehensive questionnaire
(t0–t4) under the supervision of trained study nurses. The questionnaire comprised demographic
characteristics, psychological symptoms (e.g., depression) and constructs (e.g., stress, early life events,
affect, coping), physical ailments, and information regarding alcohol consumption and medication
intake. Blood samples were collected at baseline (t0) and 5 months follow-up (t2) and DXA bone
densitometry measurements took place at the last follow up (t4).
4.2.3. Psychometric Measures
Early life stress was measured retrospectively, comprising experiences of childhood maltreatment
and stressful life events during childhood. The Childhood Trauma Screener (CTS) [107], a 5-item
screening tool of the 28-item Childhood Trauma Questionnaire (CTQ) [108,109], assesses five types of
childhood maltreatment, such as emotional, physical, and sexual abuse, plus emotional and physical
neglect. Each item is scored on a five-point rating scale from “never true” (1) to “very often true”
(5). In accordance with Glaesmer et al. [107], we classified participants at risk if they rated at least
mild forms of childhood abuse or neglect. We additionally controlled for response bias by the 3-item
Minimization-Denial subscale from the CTQ, and excluded participants when indicated. Cronbach’s
Alpha was previously specified with 0.76 [110].
Stressful life events were assessed by a modified version of the Inventory of Stressful Life Events
(ILE; [111]). Participants rated 34 adverse life events regarding occurrence, frequency and year of
occurrence. The accumulation of stressful, life-changing events at different stages of development was
counted for every participant, in this analysis focusing on childhood (ILE child ≤ 12 years). The scores
ranged between 0 (no strain) and 4 (high strain). Cronbach´s Alpha for ILE was 0.83.
Depressive symptoms and severity were assessed using the Beck Depression Inventory-II
(BDI-II) [112,113]. Internal consistency in the sample was Cronbach’s Alpha 0.89.
Furthermore, confounding factors like sociodemographic and biometric characteristics and study
site were assessed.
4.2.4. Serum Bone Marker Measurement
Blood samples were drawn from the arm in the morning (7–9 a.m.), collected in plain blood
collection tubes, allowed to clot at room temperature for 30 min, followed by centrifugation, isolation
of serum and freeze-storage until further analysis. Bone-related blood markers (OC, PINP, CTX-I) were
analyzed in serum samples by electrochemiluminescence immunoassays “ECLIA” (12149133 122 for
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Osteocalcin, 03141071 190 for PINP, 11972308 122 for CTX-I, all from F. Hoffmann-La Roche, Ltd., Basel,
Switzerland).
4.2.5. DXA Measurement
Bone mineral density (BMD) was measured by DXA bone densitometry measurement
(Lunar, Prodigy Advance, GE Healthcare, Madison, WI, USA) in the lumbar spine (lumbar vertebral
bodies L1-L4) and both hips. Parameters are given as mean values (M) of the left and right site: G (total),
H (collum femoris), S (corpus femoris), T (trochanter major), and L1L4 (lumbar vertebral bodies L1-L4).
4.3. Statistical Analysis
Data consistency was checked, screened for outliers and analyzed descriptively. Continuous
variables were also tested for normality by using skewness, kurtosis, omnibus test; variance
homogeneity was proven by variance ratio and Levene test.
For the examination of Aim 1 (mouse model), Student t-test for equal or Aspin–Welch unequal
variance test were performed, using multiple t-test and adjusted for multiple comparison by Holm–Sidak
method (alpha = 0.05). Since body weight was found to be significantly different, ANCOVA models
with body weight as covariate were applied for µCT data to compute corresponding means at their
covariate means (i.e., least square means at covariate mean for body weight of 16.41). In addition,
blocking on total body weight was used as a means of accounting for collinearity in analyses of variance,
and mediation analyses were conducted using linear regression models to identify mediation effects
between body weight and bone microstructure. All reported tests are two-sided, and p-values < 0.05
are considered as statistically significant.
Regarding Aim 2 (human model), multiple regression models were applied. Statistical models
were cross-sectional and controlled for age, gender, study sites and additionally body weight for
DXA measurements.
Statistical analyses were conducted using NCSS (NCSS 10, NCSS, LLC. Kaysville, UT, USA),
STATISTICA 13 (TIBCO, Palo Alto, CA, USA), IBM SPSS 25 (IBM, Armonk, NY, USA) and the statistical
software R [114,115].
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/21/18/
6634/s1.
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ADRB2 adrenoceptor beta 2
ANCOVA analysis of covariance
AVD apparent volume density
BDI-II Beck Depression Inventory Revision
BDNF brain derived neurotrophic factor
BMD bone mineral density
BMD_G bone mineral density general
BMD_H bone mineral density collum femoris
BMD_L1L4 bone mineral density lumbar vertebralis bodies 1–4
BMD_S bone mineral density corpus femoris
BMD_T bone mineral density trochanter major
BV bone volume
BS specific bone surface
CGRP calcitonin gene related peptide
ChAT choline acetyltransferase
CHRNA7 cholinergic receptor nicotinic alpha 7 subunit
CTQ Childhood Trauma Questionnaire
CTS Childhood Trauma Screener
CTX-I c-terminal telopeptide of type I collagen





[Der Einfluss unterschiedlicher Behandlungs-settings auf den Therapieerfolg bei Patienten
mit depressiven Erkrankungen in der Rehabilitation]
DXA dual energy X-ray absorptiometry
ECLIA electrochemiluminescence immunoassays
ECM extracellular matrix
ELISA enzyme-linked immunosorbent assay
FITC fluorescein isothiocyanate
GAP 43 growth associated protein 43
HPA hypothalamic pituitary adrenal
ICD-10 International Classification of Diseases Version 10
IgG1 immunoglobulin G
ILE Inventory of Stressful Life Events




MSUS maternal separation and unpredictable stress
mRNA messenger ribonucleic acid
NF nerve fibers
NGF nerve growth factor
NPY neuropeptide Y
NPYR1 neuropeptide Y receptor 1
OC osteocalcin
qPCR quantitative polymerase chain reaction
PBSPGP 9.5 phosphate buffered salineprotein gene product 9.5
PINP procollagen type 1 N-terminal propeptide
PND postnatal day
RAMP1 receptor activity modifying protein 1
SAM senescence-accelerated mouse
SD standard deviation
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SP substance P
TAC1 tachykinin 1





TRKA tropomyosin receptor kinase A
Tt.Ar total area
TRKB tropomyosin receptor kinase B
TV total volume
VIP vasoactive intestinal peptide
VIPR1 vasoactive intestinal peptide receptor 1
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